A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 27, 2016

Study Completion Date

December 27, 2016

Conditions

Melanoma

Interventions

DRUG

Epacadostat

DRUG

Placebo

DRUG

ipilimumab

ipilimumab 3 mg/kg IV

DRUG

ipilimumab

Doses to be determined following the completion of Phase I of the study

Trial Locations (7)

Los Angeles

Miami

Tampa

Chicago

Durham

Philadelphia

Pittsburgh